Revenue up 46% at Rs 348 cr
On account of rise in bad loans
Asset quality worsen, as gross NPAs rise to 7.31% of gross advances as of June, from 3.39% a year ago
Total expenses of the firm were lower at Rs 95,537.82 crore against Rs 98,927.09 crore in the year-ago quarter
Total earnings of the bank increased to Rs 2,250.8 crore for the quarter under review, as against Rs 2,107.09 crore a year before
Gross bad loans as a percentage of total loans rose to 1.04% from 0.94% as of end-March, which the bank said was driven by small-and-medium corporate borrowers and individuals
The company's net standalone income during the quarter under review improved by 8.28% as Rs 13,156 cr
Management says bank returning to its former efficiency parameters
Biocon and Mylan apply for regulatory approval at EU for biosimilar of anti-cancer drug Pegfilgrastim
Its consolidated turnover was up 15% at Rs 2,492 crore against Rs 2,167 crore
The company's shares ended at Rs 701.50 apiece on the BSE
The company also hopes to complete the process of the merger with parent company Vedanta Ltd by the end of March 2017
Shares of the company closed at Rs 427.75 on BSE
Shares of the company ended 0.06% lower at Rs 250.65 on BSE
Shares of the company ended 7.72% down at Rs 138.60 per scrip on BSE
MHCV domestic volume for the quarter was 22,061 units, a record high
Revenue up by 6% to Rs 803 cr
Company's revenue up by 22%
The premium end of homecare contributed to the 6.8% sales growth seen for the June quarter
Company expects IT services revenues to grow 1% in Sept quarter